Section Arrow
GKOS.NYSE
- Glaukos Corp
Quotes are at least 15-min delayed:2026/11/20 17:45 EST
After Hours
Last
 235
-2.31 (-0.97%)
Bid
210
Ask
237.38
High 238.76 
Low 210 
Volume 77.98K 
Regular Hours (Closed)
Last
 237.31
-0.79 (-0.33%)
Day High 
244.545 
Prev. Close
238.1 
1-M High
255.185 
Volume 
1.09M 
Bid
210
Ask
237.38
Day Low
233.4 
Open
238.87 
1-M Low
168 
Market Cap 
14.09B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 239.76 
20-SMA 226.79 
50-SMA 189.55 
52-W High 255.185 
52-W Low 93.96 
Exchange NYSE 
Valuation Estimation
EPS (Current/Estimated)
-2.95/-0.07
Enterprise Value
14.20B
Balance Sheet
Book Value Per Share
12.12
Cash Flow
Cash Flow Yield
0.00
Income Statement
Total Revenue
383.48M
Operating Revenue Per Share
5.13
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
BSXBoston Scientific Corp41.98-1.01-2.35%18.14PE
After Hours 42.5 +0.52 +1.24%
PACBPacific Biosciences of California1.63-0.13-7.39%-- 
After Hours 1.6861 +0.0561 +3.44%
MDTMedtronic plc99.94-0.67-0.67%24.78PE
After Hours 99.5 -0.44 -0.44%
QSIQuantum-Si0.909-0.161-15.05%-- 
After Hours 0.9599 +0.0509 +5.60%
ABTAbbott Laboratories103-0.87-0.84%38.76PE
After Hours 104.33 +1.33 +1.29%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.